- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07568847
Improving Hospital-To-Methadone Clinic Connection Using Implementation Support for Patients With Opioid Use Disorder (HOTPIN-IF)
Facilitating In-Hospital Opioid Treatment Program Intakes to Support Hospital to OTP Linkage Among Hospitalized Patients With Opioid Use Disorder: An Implementation Trial in Four Hospitals
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The purpose of this study is to test whether a hospital-based approach can improve connection to methadone treatment after discharge. The approach includes completing OTP intake during hospitalization and supporting hospital teams through an implementation strategy called implementation facilitation (IF). This study also aims to understand how well the approach can be adopted and sustained across different hospitals. This is a multi-site clinical trial conducted at four hospitals. The study uses a hybrid type 2 implementation-effectiveness design, meaning it evaluates both patient outcomes and how the intervention is implemented. The study uses an incomplete stepped wedge cluster randomized design. In this design:
- All hospitals begin in a usual care phase
- Hospitals are randomly assigned a time to switch to the intervention
- Over time, each hospital transitions from usual care to the intervention phase
- This allows each hospital to serve as its own comparison
During the usual care phase, patients receive standard care, which includes referral to an OTP at discharge. During the intervention phase, hospital teams receive implementation support to help complete OTP intake during the hospital stay. The intervention is an implementation strategy designed to support hospital teams in completing OTP intake during hospitalization.
The study uses the RE-AIM framework to evaluate outcomes:
- Reach: The number and characteristics of patients who complete OTP intake and connect to care.
- Effectiveness: The primary outcome is connection to an OTP after hospital discharge (for example, within 7 days). Secondary outcomes may include engagement in treatment at 30 and 90 days, healthcare use, and mortality.
- Adoption: The proportion of hospital clinicians and teams who use the new workflows and complete OTP intake.
- Implementation: How well the intervention is delivered, including fidelity to core components, adaptations, and resources used.
- Maintenance: Whether the intervention is sustained over time after initial implementation.
The study will also assess implementation costs and identify barriers and facilitators to adoption.
Participants are adults with OUD who are hospitalized and interested in starting methadone treatment. Participants must be willing to connect to a methadone clinic after discharge.
Data will be collected from multiple sources, including:
- Electronic health records (EHRs) from participating hospitals
- Data from opioid treatment programs (when available)
- Study questionnaires completed during enrollment
- Administrative data on healthcare use
- National Death Index data for mortality outcomes
- Data will be combined across sites using a structured data approach to ensure consistency.
The analysis will evaluate:
- Differences in OTP connection rates
- Changes in treatment engagement over time
- Variation across hospitals
- Implementation outcomes and costs
- Qualitative data from interviews and observations may also be used to understand how the intervention works in real-world settings.
This study addresses a major gap in care for people with OUD. Improving connection to methadone treatment after hospitalization has the potential to reduce overdose deaths, improve health outcomes, and reduce healthcare use. By testing both effectiveness and implementation, this study will provide practical information for scaling this approach across hospitals.
If successful, this model could be widely adopted to improve access to life-saving treatment for people with OUD.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Susan L Calcaterra, MD, MPH, MS
- Número de teléfono: 2487035947
- Correo electrónico: susan.calcaterra@cuanschutz.edu
Copia de seguridad de contactos de estudio
- Nombre: Sarah Mann, MA
- Correo electrónico: sarah.mann@cuanschutz.edu
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age ≥18 years
- Hospitalized with DSM-5 opioid use disorder, confirmed by clinical assessment
- Eligible for methadone treatment as determined by the clinical team
- Not currently enrolled in an Opioid Treatment Program (OTP)
- Anticipated discharge to the community
- Willing to initiate methadone and follow up at a partnering OTP
Exclusion Criteria:
- Current enrollment in an Opioid Treatment Program (OTP)
- Planned discharge to a correctional or institutional setting that precludes OTP follow-up
- Medical or psychiatric instability that precludes safe methadone initiation or completion of study procedures
- Inability to provide required information for OTP intake due to impaired cognition or altered mental status
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: N / A
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Usual Care
Standard hospital-to-OTP referral processes without implementation facilitation
|
Participants receive care at sites after rollout of Implementation Facilitation (IF) to support HOTPIN workflows. Focus on completing in-hospital OTP intake, including: Medical assessment Screening labs Methadone initiation Transportation coordination Supported by: External facilitators Learning collaboratives Workflow integration into the EHR |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
7-Day Hospital-to-OTP Linkage
Periodo de tiempo: Measured within 7 days following hospital discharge
|
The primary outcome is whether a participant successfully connects to an Opioid Treatment Program (OTP) within 7 days after hospital discharge. Connection" (linkage) is defined as: Completion of OTP intake and/or attendance at the OTP, and Receipt or continuation of methadone treatment at the OTP |
Measured within 7 days following hospital discharge
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
30-Day OTP Engagement
Periodo de tiempo: 30 days after hospital discharge
|
Description: Proportion of participants who remain engaged in methadone treatment at an Opioid Treatment Program (OTP) within 30 days after hospital discharge. Defined by ongoing dosing or documented attendance at the OTP Reflects short-term treatment retention |
30 days after hospital discharge
|
|
90-Day OTP Engagement (Retention)
Periodo de tiempo: Within 90 days after hospital discharge
|
Description: Proportion of participants who remain engaged in methadone treatment at an OTP within 90 days after hospital discharge. Defined by continued dosing records or clinic attendance Reflects longer-term treatment retention |
Within 90 days after hospital discharge
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Healthcare Utilization After Discharge
Periodo de tiempo: 90 days following hospital discharge
|
Description: Rates of emergency department visits and hospital readmissions following the index hospitalization. Assessed using hospital administrative and EHR data |
90 days following hospital discharge
|
|
All-cause mortality following hospital discharge.
Periodo de tiempo: 90 days after hospital disharge
|
Assessed using linkage to the National Death Index (NDI)
|
90 days after hospital disharge
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Susan L Calcaterra, MD, MPH, MS, University of Colorado, Denver
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 26-0455
- 1R01DA063733-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
We will share de-identified individual participant data (IPD) using a controlled access process (not open download)
We will require:
Data Use Agreement (DUA) IRB approval or exemption data security plan
We will exclude:
Direct identifiers Anything restricted under 42 CFR Part 2 without proper authorization
Marco de tiempo para compartir IPD
Time Frame:
Data will be available beginning 12 months after publication of the primary results and ending 5 years after publication.
Criterios de acceso compartido de IPD
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .